Verona Pharma (VRNA) Stock Statistics & Valuation Metrics

Verona Pharma has a market cap or net worth of $4.89B. The enterprise value is $2.23B.

Verona Pharma has 79.11M shares outstanding. The number of shares has decreased by -2.65% in one year.

Verona Pharma’s return on equity (ROE) is -0.85 and return on invested capital (ROIC) is -37.89%.

The current PE Ratio of Verona Pharma is -21.84. Verona Pharma’s PEG ratio is -0.11.

In the last 12 months, Verona Pharma had revenue of $42.28M and earned -$173.48M in profits. Earnings per share was -$0.27.

In the last 12 months, operating cash flow was -$122.20M and capital expenditures -$535.00K, giving a free cash flow of -$122.79M billion.

Verona Pharma pays an annual dividend of , resulting in a dividend yield of

Verona Pharma upcoming earnings date is Apr 29, 2025, TBA.

Verona Pharma as a current ratio of 10.63, with Debt / Equity ratio of 0.01

In the past 12 months, Verona Pharma has paid $8.86M in taxes.

Verona Pharma EV to EBITDA ratio is -215.81, with an EV/FCF ratio of -244.64.

Verona Pharma has $399.76M in cash and marketable securities with $122.70M in debt, giving a net cash position of -$277.06M billion.

Gross margin is 93.89%, with operating margin of -365.73%, and net profit margin of -410.18%.

The average price target for Verona Pharma is $80.29, which is 11.43% higher than the current price. The consensus rating is Strong Buy